Nutriband Inc. (NTRB) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Orlando, FL, United States. The current CEO is Gareth Sheridan.
NTRB has IPO date of 2021-10-01, 13 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $49.43M.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
